Increased release of vascular prostacyclin-like activity after long-term treatment of diabetic rats with Bay g 6575.
10 male Wistar rats were made diabetic by an intravenous injection of streptozotocin. 10 sex and age-matched rats served as control animals. 5 of the diabetic and 5 of the control rats received Bay g 6575 (20 mg/kg orally) for 6 days each week throughout the whole study period (9-11 months). From these animals aorta was removed for prostacyclin bioassay based upon its platelet aggregation inhibitory effect. The diabetic rats treated with Bay g 6575 released significantly more prostacyclin than the controls (p less than 0.005). Our study suggests further experiments in other animal models more susceptible to diabetic vascular lesions than the rat model to evaluate the possible beneficial role of the treatment with Bay g 6575.
D000236:Adenoma / Q000150:complications; D000818:Animals; D001011:Aorta / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D011464:Epoprostenol / Q000097:blood*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000150:complications; D008297:Male; D011453:Prostaglandins / Q000097:blood*; D011720:Pyrazoles / Q000627:therapeutic use*; D047069:Pyrazolones; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D005343:Fibrinolytic Agents; D011453:Prostaglandins; D011720:Pyrazoles; D047069:Pyrazolones; D011464:Epoprostenol; C018845:nafazatrom